Does the media prefer ANVS or ANIK?

In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.53 beat Annovis Bio's score of -0.13 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANIK or SVRA?

In the previous week, Anika Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Anika Therapeutics and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Anika Therapeutics' score of 0.53 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIK or CRVS?

In the previous week, Anika Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Corvus Pharmaceuticals. Anika Therapeutics' average media sentiment score of 0.53 beat Corvus Pharmaceuticals' score of 0.48 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CVAC or ANIK?

Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 5.72%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media favor ANIK or MLTX?

In the previous week, Anika Therapeutics and Anika Therapeutics both had 3 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Anika Therapeutics' score of 0.53 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anika Therapeutics (ANIK) Competitors

$20.81 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.81 0.00 (0.00%)

As of 05:55 AM Eastern

Compare

ANIK vs. ANVS, SVRA, CRVS, CVAC, and MLTX

Should you buy Anika Therapeutics stock or one of its competitors? Anika Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), Savara (SVRA), Corvus Pharmaceuticals (CRVS), CureVac (CVAC), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anika Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A

In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.53 beat Annovis Bio's score of -0.13 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Anika Therapeutics	-3.14%	0.20%	0.15%

Annovis Bio has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Annovis Bio presently has a consensus target price of $12.00, indicating a potential upside of 939.86%. Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 5.72%. Given Annovis Bio's higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Anika Therapeutics beats Annovis Bio on 10 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to Savara?

Anika Therapeutics (NASDAQ:ANIK) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Anika Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Savara. Anika Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Anika Therapeutics had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Anika Therapeutics and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Anika Therapeutics' score of 0.53 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 5.72%. Savara has a consensus target price of $10.00, indicating a potential upside of 86.22%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Savara	N/A	-90.28%	-68.95%

Summary

Anika Therapeutics beats Savara on 8 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to Corvus Pharmaceuticals?

Anika Therapeutics (NASDAQ:ANIK) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Anika Therapeutics presently has a consensus price target of $22.00, indicating a potential upside of 5.72%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 165.39%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anika Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Anika Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

In the previous week, Anika Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Corvus Pharmaceuticals. Anika Therapeutics' average media sentiment score of 0.53 beat Corvus Pharmaceuticals' score of 0.48 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anika Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Anika Therapeutics beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Anika Therapeutics has a consensus target price of $22.00, indicating a potential upside of 5.72%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

CureVac has a net margin of 199.92% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Anika Therapeutics	-3.14%	0.20%	0.15%

17.3% of CureVac shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anika Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Anika Therapeutics and 0 mentions for CureVac. Anika Therapeutics' average media sentiment score of 0.53 beat CureVac's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Anika Therapeutics	Positive

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

CureVac has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A

Summary

Anika Therapeutics beats CureVac on 11 of the 17 factors compared between the two stocks.

How does Anika Therapeutics compare to MoonLake Immunotherapeutics?

Anika Therapeutics (NASDAQ:ANIK) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Anika Therapeutics and Anika Therapeutics both had 3 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Anika Therapeutics' score of 0.53 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 5.72%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 98.32%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

Anika Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Summary

Anika Therapeutics beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$278.44M	$3.89B	$7.22B	$12.94B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-77.07	14.23	275.48	25.40
Price / Sales	2.47	1,431.66	648.15	82.07
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	2.09	15.73	10.60	6.32
Net Income	-$10.88M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-1.79%	-1.32%	-0.24%	0.42%
1 Month Performance	-4.45%	-4.51%	-2.67%	-3.30%
1 Year Performance	133.82%	37.78%	18.16%	5.33%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	3.2353 of 5 stars	$20.81 flat	$22.00 +5.7%	+133.8%	$278.44M	$112.82M	N/A	235	Analyst Forecast
ANVS Annovis Bio	2.2225 of 5 stars	$1.12 -2.2%	$12.00 +976.2%	-50.5%	$47.51M	N/A	N/A	3	Analyst Upgrade
SVRA Savara	2.0771 of 5 stars	$5.23 -2.2%	$10.00 +91.4%	+52.1%	$1.07B	N/A	N/A	70	Positive News
CRVS Corvus Pharmaceuticals	2.1671 of 5 stars	$12.72 -3.0%	$33.33 +162.1%	+114.0%	$1.07B	N/A	N/A	37	Positive News
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, SVRA, CRVS, CVAC, and MLTX

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to Savara?

Summary

How does Anika Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Anika Therapeutics compare to CureVac?

Summary

How does Anika Therapeutics compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, SVRA, CRVS, CVAC, and MLTX

How does Anika Therapeutics compare to Annovis Bio?

Which has better earnings & valuation, ANVS or ANIK?

Does the media prefer ANVS or ANIK?

Is ANVS or ANIK more profitable?

Which has more risk & volatility, ANVS or ANIK?

Do analysts prefer ANVS or ANIK?

Do institutionals and insiders hold more shares of ANVS or ANIK?

Summary

How does Anika Therapeutics compare to Savara?

Which has more volatility and risk, ANIK or SVRA?

Which has preferable valuation and earnings, ANIK or SVRA?

Do insiders & institutionals hold more shares of ANIK or SVRA?

Does the media prefer ANIK or SVRA?

Do analysts prefer ANIK or SVRA?

Is ANIK or SVRA more profitable?

Summary

How does Anika Therapeutics compare to Corvus Pharmaceuticals?

Is ANIK or CRVS more profitable?

Do analysts prefer ANIK or CRVS?

Do insiders and institutionals hold more shares of ANIK or CRVS?

Which has stronger earnings & valuation, ANIK or CRVS?

Does the media favor ANIK or CRVS?

Which has more risk & volatility, ANIK or CRVS?

Summary

How does Anika Therapeutics compare to CureVac?

Do analysts recommend CVAC or ANIK?

Is CVAC or ANIK more profitable?

Do insiders & institutionals hold more shares of CVAC or ANIK?

Does the media prefer CVAC or ANIK?

Which has more risk & volatility, CVAC or ANIK?

Which has stronger earnings and valuation, CVAC or ANIK?

Summary

How does Anika Therapeutics compare to MoonLake Immunotherapeutics?

Do insiders and institutionals have more ownership in ANIK or MLTX?

Which has more risk & volatility, ANIK or MLTX?

Does the media favor ANIK or MLTX?

Do analysts rate ANIK or MLTX?

Which has preferable valuation & earnings, ANIK or MLTX?

Is ANIK or MLTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools